New at CADTH - February 2019
Fri, 08 Feb 2019 00:00:00 -0500
Italiano
Fri, 08 Feb 2019 00:00:00 -0500
Inter-individual variability in drug response is one of the most relevant issues for the proper management of patients in clinical practice. The team of health professionals is faced with possible unexpected variations in individual responses to medicinal products responsible for therapeutic failures and adverse reactions, many of which are clinically relevant.
Preventing, detecting and treating pain is today an ethical imperative that strongly involves the paediatric world1,2. In hospital the measurement of pain should have the same relevance as that of the essential vital parameters and be constantly monitored at all the stages of hospital treatment. Despite this, the customary procedure for medications for pain control is still insufficient.
The use of aspirin (ASA) in the primary prevention of cardiovascular diseases has been discussed in recent years for the uncertainty deriving from the results of the studies, so much so that the most recent guidelines do not recommend their use1.
Il progetto MEREAFAPS (Monitoraggio epidemiologico delle reazioni e degli eventi avversi da farmaci in pronto soccorso) è nato in Lombardia nel 2006.
Le Aziende che producono medicinali sartani per
il controllo della pressione arteriosa (noti anche
come bloccanti del recettore dell'angiotensina II) sono tenuti a rivedere i
loro processi produttivi in modo da non produrre impurezze della classe delle
nitrosamine.
80.211.154.110